The Alliance of Glycobiologists for Cancer Research, a consortium of nine Tumor Glycomics Laboratories, is working to understand how cancer-related dynamics of complex carbohydrates contributes to the initiation and progression of tumors. Insights gained from these studies will then lead to the development of new, validated clinical biomarkers for early detection of cancer.
The mission of the Alliance is to study structure and function of glycans in relation to cancer development towards developing clinically useful biomarkers for the early detection of cancer by using a variety of approaches and technologies. This charge also requires extensive collaborations across institutions with different skills and facilities to accelerate glycan-based biomarkers to the forefront of NCI's efforts to detect and diagnose cancer at early stages.
The unique needs of the laboratories for technologies embracing carbohydrate chemistry are further supported by programs of:
- The National Institutes of Health Office of Strategic Coordination that oversees the NIH Common Fund supports a major program in Glycoscience for the development of new technologies, tools, synthetic strategies, and informatics capabilities relevant to the specific needs of researchers in glycobiology;
- The National Institute of General Medical Sciences (NIGMS) supported the Consortium for Functional Glycomics (CFG);
- The Early Detection Research Network (EDRN) of NCI with whom the Alliance will work closely with to validate promising glycans for clinical use.
A Steering Committee (SC) representing all Tumor Glycomics Laboratories along, representatives from the partnering programs, and program staff from NCI integrates the activities of the Alliance.
Read more About the Alliance.